Imatinib mesylate—gold standards and silver linings

Author： Peggs K.  

Publisher： Springer Publishing Company

ISSN： 1591-8890

Source： Clinical and Experimental Medicine, Vol.4, Iss.1, 2004-04, pp. : 1-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Precipitation of porphyria cutanea tarda by imatinib mesylate?

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 121, Iss. 2, 2003-04 ,pp. : 375-375

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases

By Eklund Kari   Joensuu Heikki  

Annals of Medicine, Vol. 35, Iss. 8, 2003-12 ,pp. : 640-640

Informa Healthcare

Access to resources Recommend Favorite

Promyelocytic Crisis of Chronic Myelogenous Leukaemia during Imatinib Mesylate Treatment

By  

Acta Haematologica, Vol. 117, Iss. 4, 2006-12 ,pp. : 191-196

Karger

Access to resources Recommend Favorite

Drug-Induced Pneumonitis Associated with Imatinib Mesylate in a Patient with Idiopathic Pulmonary Fibrosis

By  

Respiration, Vol. 75, Iss. 3, 2006-01 ,pp. : 350-354

Karger

Access to resources Recommend Favorite

Squamous cell carcinoma in a chronic myelogenous leukemia patient treated with imatinib mesylate

By  

THE JOURNAL OF DERMATOLOGY, Vol. 42, Iss. 3, 2015-03 ,pp. : 338-339

John Wiley & Sons Inc

Access to resources Recommend Favorite